Compare Chubb Ltd (CB) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chubb Ltd vs Mesoblast Limited — how do they compare? Chubb Ltd trades at $344.03 (market cap $134.28B), while Mesoblast Limited trades at $17.69 (market cap $2.12B). The key difference: Chubb Ltd is far larger — about 63.3× Mesoblast Limited's market cap, and Chubb Ltd pays a 1.18% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| CB | MESO | |
|---|---|---|
Market Cap | $134.28B | $2.12B |
Sector | Financials | Technology |
52-Week High | $361.17 | $20.96 |
52-Week Low | $265.99 | $10.96 |
Enterprise Value | $155.34B | $2.13B |
Dividend Yield | 1.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chubb (CB) trades at $354.74, up 1.99% today, with a bullish technical outlook supported by moving averages and strong fundamental performance. Recent earnings beats, including Q1 2026 EPS of $6.82 versus $6.60 expected, highlight robust profitability with a net income margin of 18.46% and ROE of 16.2%. The company maintains disciplined capital deployment, with a recent $1.02 dividend declared for H1 2026.
The stock offers a compelling value with a P/E of 12.55 and consensus price target of $361.67, though near-term risks include catastrophe losses and softer commercial pricing. Long-term growth is supported by premium expansion and investment income, but investors should monitor underwriting margins and market volatility.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chubb Ltd
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
Read more on CB →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
